![Tassos Konstantinou](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tassos Konstantinou
Directeur/Bestuurslid bij Oxford Biotrans Ltd.
Profiel
Tassos Konstantinou is currently a Non-Executive Director at Oxford Biotrans Ltd.
and a Director at Kynos Therapeutics Ltd.
He previously held positions as a Director at Oxular Ltd.
and STORM Therapeutics Ltd.
Konstantinou holds a doctorate from the University of Oxford and a graduate degree from The University of Chicago.
Actieve functies van Tassos Konstantinou
Bedrijven | Functie | Begin |
---|---|---|
Oxford Biotrans Ltd.
![]() Oxford Biotrans Ltd. Chemicals: Major DiversifiedProcess Industries Oxford Biotrans Ltd. develops and commercializes enzymatic process technologies that produce chemical compounds. The firm produces chemicals using ‘green’ biotransformation technology to starting materials into initial focus is on flavors and fragrances using its proprietary understanding of P450 enzyme catalyst technology. The company was founded by Luet Lok Wong in 2013 and is headquartered in Milton Park, the United Kingdom. | Directeur/Bestuurslid | - |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Tassos Konstantinou
Bedrijven | Functie | Einde |
---|---|---|
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Directeur/Bestuurslid | - |
Oxular Ltd.
![]() Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Directeur/Bestuurslid | - |
Opleiding van Tassos Konstantinou
University of Oxford | Doctorate Degree |
The University of Chicago | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Oxular Ltd.
![]() Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Oxford Biotrans Ltd.
![]() Oxford Biotrans Ltd. Chemicals: Major DiversifiedProcess Industries Oxford Biotrans Ltd. develops and commercializes enzymatic process technologies that produce chemical compounds. The firm produces chemicals using ‘green’ biotransformation technology to starting materials into initial focus is on flavors and fragrances using its proprietary understanding of P450 enzyme catalyst technology. The company was founded by Luet Lok Wong in 2013 and is headquartered in Milton Park, the United Kingdom. | Process Industries |
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Health Technology |